<code id='15E913A7AB'></code><style id='15E913A7AB'></style>
    • <acronym id='15E913A7AB'></acronym>
      <center id='15E913A7AB'><center id='15E913A7AB'><tfoot id='15E913A7AB'></tfoot></center><abbr id='15E913A7AB'><dir id='15E913A7AB'><tfoot id='15E913A7AB'></tfoot><noframes id='15E913A7AB'>

    • <optgroup id='15E913A7AB'><strike id='15E913A7AB'><sup id='15E913A7AB'></sup></strike><code id='15E913A7AB'></code></optgroup>
        1. <b id='15E913A7AB'><label id='15E913A7AB'><select id='15E913A7AB'><dt id='15E913A7AB'><span id='15E913A7AB'></span></dt></select></label></b><u id='15E913A7AB'></u>
          <i id='15E913A7AB'><strike id='15E913A7AB'><tt id='15E913A7AB'><pre id='15E913A7AB'></pre></tt></strike></i>

          Home / hotspot / fashion

          fashion


          fashion

          author:comprehensive    Page View:9
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In